

DL Medicine teams up with Pfizer for new drug discovery

07 February 2018 | News

DL Medicine investors include Anlong, a healthcare-focused fund backed by the Chinese Academy of Sciences, and HitGen, a drug discovery research biotech based in Chengdu, China.



China based biotechnology company NetVation DL Medicine has entered into a two-year research collaboration with Pfizer Inc to produce new chemical entities against pre-selected targets from multiple therapeutic areas.

DL Medicine investors include Anlong, a healthcare-focused fund backed by the Chinese Academy of Sciences, and HitGen, a drug discovery research biotech based in Chengdu, China.

Research conducted under this collaboration will utilize HitGen's DNA-encoded libraries to validate early targets, identify novel chemical matter, and conduct lead optimization. Compounds that meet specific requirements will be advanced further in the discovery process. Additional screening technology platforms will also be utilized.

DL Medicine utilizes resources, funding and emerging technologies from the expanding biotechnology capabilities of the growing life sciences industry in China and employs novel approaches to identify and develop new drug candidates.